Current Research Studies

SkyPASS: A prospective, non-interventional (NIS), long-term, post-authorisation safety study (PASS) of patients treated with lonapegsomatropin.

ASND0033 SkyPASS

Condition(s): Other
Clinicaltrials.gov ID: NCT05775523

What is the goal of the study?

This prospective, non-interventional, long-term, post-authorisation safety study of patients treated with lonapegsomatropin will seek to further assess the important potential risks (neoplasms, type 2 diabetes mellitus) and the missing information (long-term safety including adverse drug reactions potentially related to methoxypolyethylene glycol (mPEG) exposure) as per the Risk Management Plan (RMP). This study is a required regulatory study within the RMP.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Patricia Fechner
Study Team Member: ECR Endocrine Research, endocrineresearch@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.